Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViroPharma’s Failed Exclusivity Bid For Vancocin Could Spur Congress To Act

Executive Summary

FDA’s decision that vancomycin oral capsules do not qualify for Hatch-Waxman marketing protection under a 2008 law could become the focus of a legislative “fix” in pending user fee bills if lawmakers disagree with the agency’s conclusion that only approval of a “significant new use” for older antibiotics warrants exclusivity.

Advertisement

Related Content

Senate Accelerated Approval Draft Needs “FAST” Changes, House Members Say
Vancocin Generics Launch As FDA Finds ViroPharma’s Label Fails “Significant New Use” Test
Orphan Antibiotics? Woodcock Says It May Be Possible If IDSA’s New Pathway Is Implemented
Labeling For Optimer's Dificid Includes Data On Ability To Sustain Cure Post-Treatment
Lipitor Generics: FDA Says Mylan Has No Standing To Sue (Until June 28?)
FDA's Decision-Making Process For ANDA Approval Standards Questioned In Vancomycin Case; Would Process Changes Alter The Outcome?
Generic Vancocin Gets Cmte. Endorsement, But So Do New Brand Products
Generic Approval Standards For Vancomycin Tightened In FDA Draft Guidance
“Old” Antibiotics May Get Exclusivity Under New Law; 10 Drugs Could Benefit

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054368

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel